• Complex gene/environment interactions shaped how antidepressants affect 5-HT 1A/1B receptors.
Introduction
Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are commonly used to treat major depressive disorder (MDD). These antidepressants exert their therapeutic effects via various neurotransmitter systems, including the serotonin (5-HT) system [28] . However, clinical response to antidepressants is highly variable, with only about a third of patients attaining remission [17] . Considerable evidence suggests that, aside from any putative placebo effect, this variability in antidepressant response arises from a gene-environment (GxE) interaction; this includes events that unfold during early-life development, and may subsequently influence behavior, treatment outcome, and serotonergic function [10, 12, 16, 26, 31] . Nevertheless, it is unclear how antidepressants interact with GxE cascades to influence the serotonergic system in ways that contribute to variability in antidepressant response.
Given the difficulties inherent in conducting such work in humans, rodents pose an excellent and viable alternative. In contrast to clinical studies, which are invariably impacted by uncontrollable environmental and genetic/ethnic differences, preclinical studies using animal models of depression offer several key advantages, including the well-controlled environmental setting and similar genetic background. While a number of suitable rodent models exist, we selected the Flinders sensitive line (FSL), a well-established genetic rat model of depression that meets face-, construct-, and predictive-validity criteria [20] . The FSL strain was derived from Sprague-Dawley (SD) rats through a selective breeding program for increased sensitivity to the anticholinesterase compound di-isopropyl fluorophosphates (DFP). Flinders resistant line (FRL)-the control counterpart-exhibit low sensitivity to DFP. Notably, several neurochemical and behavioral studies comparing FSL and FRL rats have reported differences in 5-HT levels and neurochemistry, antidepressant effects, and depression-like phenotypes [3, 6, 9, 14, [21] [22] [23] [24] .
While rodent models such as the FSL capture genetic risk, they also enable investigators to examine the delicate interplay between genetic and environmental vulnerabilities. This is particularly important in the context of MDD because environmental factors affect both pathophysiology and treatment outcome. In particular, adverse early-life events (e.g., childhood maltreatment) increase susceptibility to MDD into adulthood and modulate treatment outcome [2, 26] . In conjunction with genetic or epigenetic factors, the effects of early-life events may alter brain neurochemistry, including that of the serotonergic system [4, 15] .
Both animal and human studies have implicated the abnormal function of 5-HT 1A and 5-HT 1B receptors in the pathophysiology of MDD and demonstrated that biochemical adaptations occur in both receptor subtypes with antidepressant treatment [25, 27] . Both receptor subtypes-expressed in prefrontal cortex (PFC) and hippocampus-regulate 5-HT firing as well as aid in serotonergic neurotransmission due to their presence both pre-and postsynaptically. Pre-synaptically, they regulate neuronal firing and 5-HT release via a negative-feedback system. Post-synaptically, they facilitate neurotransmission, which ultimately affects a myriad of physiological processes such as mood, sex, and appetite. The delayed therapeutic onset of SSRIs is believed to reflect the time necessary for the desensitization of somatodendritic 5-HT 1A autoreceptors in raphe [1] .
The present study investigated the neurochemical effects of two antidepressants from different classes-escitalopram (an SSRI) and nortriptyline (a TCA)-in a rat model with genetic (FRL vs. FSL) and/or environmental (normally-reared vs. maternally-separated rats) vulnerabilities. Quantitative in vitro autoradiography was performed to examine the interactions on5-HT 1A and 5-HT 1B receptors in both PFC and hippocampus. The study had three primary hypotheses: (1) both genetic vulnerability (modeled by rat strain) and environmental vulnerability (modeled by maternal separation) affect serotonergic neurochemistry; (2) a GxE interaction would emerge that would further affect serotonergic neurochemistry; and (3) The GXE interaction would be selectively modified by antidepressant treatment. The three hypotheses were tested within the context of an omnibus statistical model-i.e., a strain-by-stress-bytreatment (three-way) interaction.
Material and methods

Study design
The three-way interaction (2 × 2 × 3 matrix) on the serotonergic system was examined as shown in Fig. 1 .
Maternal separation and antidepressant treatment
Maternal separation and antidepressant treatment were performed as previously described [6, 21, 22] . Briefly, the study used only male rats housed in pairs in an 1800 cm 2 cage under a 12 h light/dark reverse cycle at 21 • C, relative humidity 55%, and food and water ad libitum. Post-natal day 0 (PND0) was designated as the day of birth. To model early-life stress, half of the pups were separated from their mothers for 180 min/day for 12 days starting at PND2.
On PND43, an equal number of rats in each group was randomly assigned to 30-day dietary supplementation (diet prepared by Lactamin AB, Sweden) with either escitalopram (0.34 g/kg for the first three weeks, 0.41 g/kg during the rest of the experiment), or nortriptyline (0.34 g/kg), or vehicle. The daily administered dose was 25 mg/kg for escitalopram and 20 mg/kg for nortriptyline. Antidepressant serum concentrations were not measured; however, several prior studies found that the selected oral doses provide serum concentrations of 15-35 ng/mL (AAM obtained proprietary results in collaboration with Lundbeck A/S and Pfizer), which are typically used to model therapeutic concentrations in humans. Average food pellet intake during the treatment period was 22 g/rat/day. No difference in food consumption or total brain weight was observed between genotypes. However, a significant weight difference emerged between the strains (FRL = 209 ± 2.4 vs. FSL = 196 ± 2.0).
At the end of the study, rats were sacrificed, and brains were immediately harvested and frozen at −80 • C. Brain was sectioned (14 m) using a microtome-cryostat (−20 • C) and mounted on gelatin-coated slides. The Stockholm Ethical Committee for the Protection of Animals approved the study.
Drugs and radioligands
[ 125 I]MPPI and [ 125 I]-(±)cyanopindolol were purchased from PerkinElmer (Massachusetts, USA). 5-HT, 8-OH-DPAT, isoprenaline, and all other reagents used in the study were purchased from Sigma (Sweden).
[ 125 I] Autoradiography
[ 125 I]Autoradiography was performed as previously described with minor modifications [13, 30] 
Data analysis
Autoradiograms were quantified using NIH ImageJ (1.44p) (http://rsbweb.nih.gov/ij/). Optical densities were normalized per area and converted into fmol/mg tissue based on the microscale standards by using nonlinear regression fit (GraphPAD Prism). Specific binding was determined by subtracting nonspecific from total binding. In all graphs, the control group was normally-reared, vehicle-administered FRL rats. All receptor binding data are expressed as percent of control calculated as: receptor Fig. 1 . A three-way study design examining strain by stress by treatment (2 × 2 × 3 matrix) interaction on the serotonergic system. In total, 105 rats were divided across 12 experimental groups.
density × 100/average receptor density of control group. All data are presented as % of control ± SEM.
Statistics
For each of the two regions and two radioligands analyzed, a full factorial ANOVA was used to examine a possible strain-by-stressby-treatment interaction. Bonferroni post-hoc tests were used to evaluate omnibus main effects and interactions. In addition, a priori comparisons were used to examine GxE interactions within the vehicle group before examining treatment effects relative to vehicle. After Bonferroni correction for multiple comparisons, the cutoff p-value was <0.0125. All analyses were run using IBM SPSS 19.0.0.1 (http://www-01.ibm.com/software/analytics/spss/).
Results
After stringent corrections for Bonferroni and multiple regions, significant strain-by-rearing-by-treatment (three-way) interactions emerged for only two of the four dependent measures: 5-HT 1A receptors in the PFC and 5-HT 1B receptors in the hippocampus.
5-HT 1A receptors
[ 125 I]MPPI autoradiograms showed specific binding in PFC and hippocampus ( Fig. 2A & B) . In the PFC, a significant strain-byrearing-by-treatment (three-way) interaction emerged (F = 5.55, df = 2.75, p < 0.01) ( Fig. 2C; Table 1 ). Initial post-hoc analyses showed that both vulnerable genotype and environment reduced 5-HT 1A receptor binding (p < 0.05). However, the effects of these two vulnerabilities were not additive. A second set of post-hoc analyses showed that only nortriptyline selectively increased 5-HT 1A receptors in the group with both vulnerabilities (p < 0.001). In the hippocampus, significant rearing-by-treatment (F = 6.32, df = 2.76, p < 0.01) and GxE (F = 11.55, df = 2.76, p < 0.01) interactions emerged. Both antidepressants increased 5-HT 1A receptors in the maternally-separated group.
5-HT 1B receptors
[ 125 I]cyanopindolol autoradiograms showed specific binding in both PFC and hippocampus (Fig. 3A & B) . In the PFC, a significant rearing-by-treatment interaction emerged (F = 12.31, df = 2.77, p < 0.001) ( Fig. 3C; Table 1 ). In the maternally-separated group, escitalopram increased 5-HT 1B receptor binding (p < 0.05).
In the hippocampus, a significant strain-by-rearing-bytreatment (three-way) interaction emerged (F = 8.30, df = 2.75, p < 0.001) (Fig. 3C) . Initial post-hoc analyses revealed that both vulnerable genotype and environment reduced hippocampal 5-HT 1B receptor binding (p < 0.05). Similar to 5-HT 1A receptors, the effects of these two vulnerabilities were not additive. Escitalopram increased binding in the group with either or both vulnerabilities (p < 0.01). In contrast, nortriptyline increased binding in the group only with either vulnerability (p < 0.001).
Discussion
This study investigated the effects of two different classes of antidepressants on serotonergic neurochemistry in rat brain using a GxE model. Antidepressant effects on 5-HT 1A/1B receptors were shaped by complex GxE interactions. Specifically, (1) both vulnerable genotype (FSL strain) and vulnerable environment (early-life stress) reduced 5-HT 1A/1B receptor binding; (2) the effects of genotype and environment were not additive; and (3) antidepressants, in general, increased 5-HT 1A/1B receptor binding (Table 1) .
With regard to the vehicle-treated rats, binding for each receptor was found to be generally lower in groups with either genetic or environmental vulnerability. However, no additive effects were associated with the two vulnerabilities, suggesting that altered serotonergic functioning stemming from either vulnerable genes or a vulnerable environment can manifest into depression/anxietylike phenotypes. This echoes prior findings demonstrating that either early-life stress or genetic manipulations that reduce the number of 5-HT 1A and/or 5-HT 1B receptors in rodents can lead to depressive/anxiety-like phenotypes [8, 29, 30] .
As regards treatment effects, unique three-way GxE interactions specific to antidepressant class emerged for PFC 5-HT 1A receptors and hippocampal 5-HT 1B receptors. Both antidepressants, in general, increased serotonergic binding. Escitalopram increased hippocampal 5-HT 1B receptor binding in groups with either or both vulnerabilities. In contrast, nortriptyline increased hippocampal 5-HT 1B receptor binding in groups with either, but not both, vulnerabilities; however, nortriptyline selectively increased PFC 5-HT 1A receptor binding only in the group with both vulnerabilities (Table 1) .
In rodents, previous neurochemical studies using similar paradigms that focused on either-but not both-genetic or environmental vulnerabilities reported altered 5-HT 1A/1B receptor binding, although findings are inconsistent [7, 19, 30] . This discrepancy may arise from several sources, including rat strain, methodology (e.g., autoradiography vs. membrane homogenate binding), brain region, duration of treatment, age, and sex. Future studies that control for as many variables as possible are necessary to clearly elucidate their interplay. Interestingly, behavioral studies in the Flinders strain found that either genetic or environmental vulnerabilities could result in depressive-like phenotypes, with complex interactions between genotype, environment, and antidepressant response [6, [21] [22] [23] [24] . For instance, studies found increased immobility in FSL vs. FRL rats, and maternal separation was found to increase immobility more in FSL than FRL rats [6, 22, 24] . Chronic escitalopram decreased immobility only in normally-reared rats, regardless of genotype [24] . On the other hand, chronic nortriptyline decreased immobility only in FSL rats, regardless of rearing [21, 23] .
In humans, a similar GxE interaction is currently favored for explaining response variability. Though the topic is presently being debated, several studies suggest that genetic polymorphisms (e.g., 5HTTLPR) and early-life stressors (e.g., physical abuse) interact to influence mood and antidepressant response [4, 10, 12, 16, 26] . The most influential GxE study suggests that 5HTTLPR-a polymorphism in the promoter region of the serotonin transporter gene (SLC6A4)-moderates the relationship between environmental stress and mood disorders [4] . In particular, this study reported a positive relationship between the number of self-reported earlylife stressors and risk for depression among individuals with one or two copies of the short allele compared with those homozygous for the long allele. However, more than 50 replication attempts, as well as three meta-analyses, have yielded inconsistent findings [5] . The inconsistency is attributable to publication bias towards positive findings, which may be statistically underpowered and susceptible to false positives [11] .
Our proof-of-concept study mirrors key aspects of the clinical scenario, in that genes, environment, and antidepressant class were explicitly manipulated. Each of these factors is known to contribute to treatment outcome. The experiment used a relatively large number of animals across the entire interaction study; however, the presence of three experimental factors yielded a design where each group contained relatively few animals, which makes it susceptible to false positives [5] . However, based on emerging-albeit inconsistently applied-standards [18] , we adopted a rigorous statistical approach, with Bonferroni correction of omnibus three-way interactions. Table 1 Antidepressant effects on the serotonergic system in rat prefrontal cortex (PFC) and hippocampus (HP) using a gene by environment (GxE) model. 
Conclusions
In conclusion, significant strain-by-rearing-by-treatment (three-way) interactions emerged for 5-HT 1A receptors in the PFC and 5-HT 1B receptors in the hippocampus. The findings demonstrate that at least three known variables interact to affect serotonergic neurochemistry, with antidepressant class modulating the delicate interplay between genes and environment in a brain region-dependent manner. Our findings provide preliminary validity for using this controlled animal model, albeit with larger sample sizes, to further understand the interaction among these three key factors in MDD: genes, environment, and antidepressant class.
